Moderna, Inc. (MUN:0QF)
Germany · Delayed Price · Currency is EUR | Market Cap | 16.72B +29.4% |
| Revenue (ttm) | 1.66B -39.9% |
| Net Income | -2.40B |
| EPS | -6.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 506 |
| Average Volume | 209 |
| Open | 37.09 |
| Previous Close | n/a |
| Day's Range | 37.09 - 39.90 |
| 52-Week Range | 20.18 - 44.09 |
| Beta | n/a |
| RSI | 65.64 |
| Earnings Date | Feb 13, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot
The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season.
Moderna (MRNA) Shares Rise as FDA Accepts mRNA-1010 Application
Moderna (MRNA) Shares Rise as FDA Accepts mRNA-1010 Application
Moderna Says FDA Will Initiate Review Of Its Seasonal Influenza Vaccine Submission; Stock Up
(RTTNews) - Moderna, Inc. (MRNA) announced that the U.S. FDA has agreed to initiate the review of its BLA for mRNA-1010, the company's investigational seasonal influenza vaccine, following a recent Ty...
Vanguard Russell 1000 Value Index Fund Buys 1,337 Shares of Moderna Inc (MRNA)
Vanguard Russell 1000 Value Index Fund Buys 1,337 Shares of Moderna Inc (MRNA)
Moderna (MRNA) Surges as FDA Revisits Stance on Flu Vaccine
Moderna (MRNA) Surges as FDA Revisits Stance on Flu Vaccine
Vanguard International Growth Fund Sells 198,561 Shares of Moderna Inc (MRNA)
Vanguard International Growth Fund Sells 198,561 Shares of Moderna Inc (MRNA)
Moderna (MRNA) Updates Regulatory Path for mRNA-1010 Flu Vaccine
Moderna (MRNA) Updates Regulatory Path for mRNA-1010 Flu Vaccine
U.S. FDA reverses course, will review Moderna's modified flu vaccine application
Moderna said on Wednesday the U.S. Food and Drug Administration has agreed to review its influenza vaccine application, reversing an earlier decision.
Moderna gains as FDA backtracks and accepts flu shot for review
Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial
A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company...
US FDA to initiate review of Moderna's influenza vaccine
Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.
Moderna, Inc.: Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to reviewModerna has receiv...
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to reviewModerna has received ...
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received...
Goldman Sachs Maintains Neutral Rating but Raises Price Target on MRNA | MRNA Stock News
Goldman Sachs Maintains Neutral Rating but Raises Price Target on MRNA | MRNA Stock News
Moderna (MRNA) Sees Bullish Activity with Increased Call Options
Moderna (MRNA) Sees Bullish Activity with Increased Call Options
Moderna Stock Rises After EU Marketing Authorization For mNEXSPIKE
Moderna shares are trading higher Tuesday after the company announced European Commission marketing authorization for its COVID-19 vaccine, mNEXSPIKE. ... Full story available on Benzinga.com
Moderna (MRNA) Price Target Raised to $35 by Evercore ISI Group | MRNA Stock News
Moderna (MRNA) Price Target Raised to $35 by Evercore ISI Group | MRNA Stock News
Vanguard U.S. Growth Fund Sells 144,076 Shares of Moderna Inc (MRNA)
Vanguard U.S. Growth Fund Sells 144,076 Shares of Moderna Inc (MRNA)
Moderna (MRNA) Secures EU Approval for New COVID Vaccine mNEXSPIKE
Moderna (MRNA) Secures EU Approval for New COVID Vaccine mNEXSPIKE
Moderna, Inc.: Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Mo...
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moder...
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moder...
Moderna Q4 2025 net loss narrows; revenue drops 30%
Moderna, Inc. (NASDAQ: MRNA) has reported a narrower net loss for the fourth quarter of fiscal 2025, when the... The post Moderna Q4 2025 net loss narrows; revenue drops 30% first appeared on AlphaStr...
Avantis U.S. Equity ETF Buys 2,873 Shares of Moderna Inc (MRNA)
Avantis U.S. Equity ETF Buys 2,873 Shares of Moderna Inc (MRNA)